Below are the most recent publications written about "Microsatellite Instability" by people in Profiles.
-
Mittal P, Battaglin F, Baca Y, Xiu J, Farrell A, Soni S, Lo JH, Torres-Gonzalez L, Algaze S, Jayachandran P, Ashouri K, Wong A, Zhang W, Yu J, Zhang L, Weinberg BA, Lou E, Shields AF, Goldberg RM, Marshall JL, Goel S, Singh IK, Lenz HJ. Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. Int J Cancer. 2025 04 15; 156(8):1583-1593.
-
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov?k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 06 08; 388(23):2145-2158.
-
Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precis Oncol. 2022 11; 6:e2200454.
-
Lefler DS, Snook AE, Bashir B. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB?and PD-L1. Immunotherapy. 2022 08; 14(11):885-902.
-
Puccini A, Poorman K, Catalano F, Seeber A, Goldberg RM, Salem ME, Shields AF, Berger MD, Battaglin F, Tokunaga R, Naseem M, Zhang W, Philip PA, Marshall JL, Korn WM, Lenz HJ. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene. 2022 06; 41(26):3455-3460.
-
Gu?guinou M, Ibrahim S, Bourgeais J, Robert A, Pathak T, Zhang X, Crott?s D, Dupuy J, Ternant D, Monbet V, Guibon R, Flores-Romero H, Lef?vre A, Lerondel S, Le Pape A, Dumas JF, Frank PG, Girault A, Chautard R, Gu?raud F, Garc?a-S?ez AJ, Ouaissi M, Emond P, Sire O, H?rault O, Fromont-Hankard G, Vandier C, Tougeron D, Trebak M, Raoul W, Lecomte T. Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer. Cell Mol Life Sci. 2022 May 08; 79(6):284.
-
Seeber A, Battaglin F, Zimmer K, Kocher F, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Marshall JL, Weinberg BA, Sackstein PE, Lim KH, Tan GS, Nabhan C, Korn WM, Amann A, Trajanoski Z, Berger MD, Lou E, Wolf D, Lenz HJ. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. Clin Cancer Res. 2022 05 02; 28(9):1863-1870.
-
Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, Soni S, Zhang W, Millstein J, Salhia B, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astsaturov I, Craig Lockhart A, Gatalica Z, Michael Korn W, Lenz HJ. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene. 2021 07; 40(30):4894-4905.
-
Huang RSP, Murugesan K, Montesion M, Pavlick DC, Mata DA, Hiemenz MC, Decker B, Frampton G, Albacker LA, Ross JS. Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. J Immunother Cancer. 2021 05; 9(5).
-
Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Marshall JL, Lockhart AC, Stafford P, Zhang J, Moretto R, Cremolini C, Korn WM, Lenz HJ. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clin Cancer Res. 2021 06 01; 27(11):3234-3242.